Citius Pharmaceuticals (CTXR) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Strategic investments and portfolio highlights

• Founders have invested over $26 million of personal funds, demonstrating strong insider commitment.

• Portfolio includes late-stage assets and one FDA-approved drug, LYMPHIR, for cutaneous T-cell lymphoma.

• Mino-Lok completed phase III trials and targets catheter-related infections in cancer patients.

• Hemorrhoid drug in phase II, aiming to be the first FDA-approved prescription for this indication.

• 2024 marked by significant milestones, including LYMPHIR approval and preparations for commercialization.

LYMPHIR approval, commercialization, and market positioning

• LYMPHIR approved in August 2024; commercialization set for January 2025.

• Added to NCCN Clinical Practice Guidelines, supporting rapid adoption and reimbursement.

• Competes with ADCETRIS and POMALYST but is considered additive due to unique treatment sequencing in CTCL.

• Clinical trials showed a 36.2% objective response rate and 84.4% reduction in skin burden.

• Drug previously marketed, reformulated, and reapproved after new phase III trials.

Corporate structure and monetization strategy

• LYMPHIR spun off into Citius Oncology, Inc., now trading as CTOR; 92% ownership retained.

• Plan to distribute Citius Oncology shares to current shareholders under favorable market conditions.

• Collaborations with University of Pittsburgh and Minnesota for immuno-oncology combinations.

• Animal studies suggest enhanced efficacy when combined with PD-1 inhibitors.

• Upcoming data presentations at major conferences to highlight new research.